All

Siolta Therapeutics Raises $12 Million in Series C Financing for Clinical Development
15 March 2024

Siolta Therapeutics Raises $12 Million in Series C Financing for Clinical Development

The company, has announced the completion of a $12 million Series C financing round. The round, co-led by SymBiosis and Khosla Ventures, reflects enthusiasm for Siolta's...

Read more
Clinical Microbiomics adds long-read DNA&RNA sequencing with DNASense acquisition
1 March 2024

Clinical Microbiomics adds long-read DNA&RNA sequencing with DNASense acquisition

Danish contract research organisation Clinical Microbiomics today reveals the acquisition of DNASense, specializing in long-read DNA and RNA sequencing technologies and...

Read more
Citryll announces the appointment of Maarten Kraan as Chief Medical Officer
13 February 2024

Citryll announces the appointment of Maarten Kraan as Chief Medical Officer

Citryll, a clinical-stage biotech company developing first-in-class therapeutics to treat immune-mediated inflammatory diseases, today announced the appointment of Maarten...

Read the press release
STARFISH Bioscience Raises €900,000 From Seventure Partners To Regenerate Soil Microbiomes By Developing The Next Generation Of Microbial Biostimulants For Sustainable Agriculture
6 February 2024

STARFISH Bioscience Raises €900,000 From Seventure Partners To Regenerate Soil Microbiomes By Developing The Next Generation Of Microbial Biostimulants For Sustainable Agriculture

Starfish Bioscience today announced that it has raised €900,000 from Seventure Partners, the world's leading investor in the microbiome field through its Health for Life...

Read the press release
SumUp taps €285M more in growth funding to weather the fintech storm
11 December 2023

SumUp taps €285M more in growth funding to weather the fintech storm

SumUp — the fintech that provides payments and related services to some 4 million small businesses in Europe, the Americas and Australia — has picked up some growth funding...

Read more
Eligo Bioscience Raises $30 Million To Write a Novel Chapter for Genetic Medicines
5 December 2023

Eligo Bioscience Raises $30 Million To Write a Novel Chapter for Genetic Medicines

Eligo Bioscience, a pioneering gene-editing company focused on addressing diseases driven by the expression of bacterial genes from the microbiome, has announced a successful...

Read more
MaaT Pharma to Present Preclinical Data at SITC on MaaT034, an Artificial Intelligence-Generated Product Aimed at Improving Patients’ Responses to Immunotherapies
31 October 2023

MaaT Pharma to Present Preclinical Data at SITC on MaaT034, an Artificial Intelligence-Generated Product Aimed at Improving Patients’ Responses to Immunotherapies

MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotech company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to...

Read more
Enterome Selected to The Leukemia & Lymphoma Society’s Therapy Acceleration Program
30 October 2023

Enterome Selected to The Leukemia & Lymphoma Society’s Therapy Acceleration Program

Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for solid and liquid malignancies and inflammatory diseases based on its unique Mimicry...

Read more
Pharma announces positive outcome following DSMB review reinforcing confidence in phase 3 on-going trial.
26 October 2023

Pharma announces positive outcome following DSMB review reinforcing confidence in phase 3 on-going trial.

Maat Pharma announces that the DSMB unanimoulsy recommended that the open-label, single arm pivotal Phase 3 clinical trial evaluating MaaT013 in acute Graft-versus-Host Disease...

Read the press release
MaaT Pharma Announces Positive Outcome Following DSMB Review Reinforcing Confidence in Phase 3 On-Going Trial in Acute Graft-versus-Host Disease with MaaT013
26 October 2023

MaaT Pharma Announces Positive Outcome Following DSMB Review Reinforcing Confidence in Phase 3 On-Going Trial in Acute Graft-versus-Host Disease with MaaT013

MaaT Pharma today announced that the DSMB unanimously recommended that the open-label, single arm pivotal Phase 3 clinical trial evaluating MaaT013 in acute Graft-versus-Host...

Read more